13th Alzheimers and Parkinsons Drug Development Summit

In 2025, the spotlight is on neurodegenerative drug development, driven by the triumph of Lecanemab and Donanemab, coupled with rapid advancements to enable presymptomatic diagnosis, reinvigorating the space with new targets, modalities, and technologies. Meanwhile significant advancements to target the likes of α-synuclein, NLRP3 and GBA suggest only a matter of time until a disease-modifying therapy emerges on the scene for Parkinson's too.

Capitalizing on a new era of revitalized hope and momentum, the 13th Alzheimer's and Parkinson's Drug Development Summit returns as the only industry-focused and end-to-end meeting, with comprehensive coverage spanning early discovery through to late clinical, regulatory, and commercial development.

Join industry's premier gathering of 150+ Alzheimer's and Parkinson's experts, with pioneering insights from the likes of Eisai, Eli Lilly, Biogen, and Roche, as they address their most pressing challenges in a collaborative atmosphere to spearhead the next wave of more truly transformative neurodegenerative therapeutics.

URLs:
Website: https://go.evvnt.com/2732400-0?pid=176 
Tickets: https://go.evvnt.com/2732400-2?pid=176 
Brochure: https://go.evvnt.com/2732400-3?pid=176

Time: 8:30 AM - 5:00 PM

Prices:
Drug Developer Pricing - Conference + Workshop Day: USD 4597.00,
Drug Developer Pricing - Conference Only: USD 2999.00,
Solution Provider Pricing - Conference + Workshop Day: USD 5563.00,
Solution Provider Pricing - Conference Only: USD 3699.00

Speakers: Alessandro Biffi, Associate Vice President, Eli Lilly and Co., Andre Matta, Executive Director, Ventus Therapeutics, Andrew Kaplan, Principal Scientist, Bristol Myers Squibb, Anick Auger, Head of Pharmacology, Ventus Therapeutics, Aparna Vasanthakumar, Senior Principal Scientist - Research, Abbvie, Beth Hoffman, Chief Executive Officer, Origami Therapeutics, Inc., Bruce Morimoto, Vice President - Drug Development, Alto Neuroscience, Carrie Rubel, Scientific Director, Biomarkers, Biogen, Chloe Whitehouse, Senior Specialist, 3D Technologies, Merck and Co, Daniel Klamer, Vice President, Business Development and Scientific Strategy, Anavex, Dean Petkanas, Co-Founder, Chairman and Chief Executive Officer, KannaLife Sciences Inc, Edmond Teng, Senior Group Medical Director, Genentech, Elena Dale, Executive Director, Neuroscience, Bristol Myers Squibb, Eric Siemers, Chief Medical Officer, Acumen Pharmaceuticals, Fraser Bocell, Senior Clinical Outcomes Assessment Scientist, Critical Path Institute (C-Path), Gul Erdemli, Global Program Regulatory Director, Novartis AG, Ivana Rubino, Vice President, Head of Global Medical Alzheimer's Disease and MS, Biogen, Jackie Olley-Williams, Senior Data Scientist, Eisai, Janaky Coomaraswamy, Director, Neuroscience Translational Medicine, Takeda Pharmaceutical Co. Ltd., Kaare Bjerregaard-Andersen, Principal Scientist, Lundbeck, Katie Planey, Chief Executive Officer and Board Member, Acelot, Inc., Kenneth Gregory Pugh, Geriatric Medicine Physician, Norton Healthcare, Luis Oliveira, Senior Associate Director - Research Programs, The Michael J. Fox Foundation for Parkinson's Research, Malú Tansey, Director of the Center for Translational Research in Neurodegenerative Disease, University of Florida, Manal Morsy, Chief Regulatory Officer, Head of Global Regulatory Affairs, Vaxxinity, Manuela Polydoro, Vice President, Head of Translational Medicine, Muna Therapeutics, Maria Maccecchini, Chief Executive Officer, Annovis Bio, Melody Libby, Patient Advocacy Lead, Alzheimer's, Biogen, Michael Erkkinen, Instructor in Neurology, Brigham and Women's Hospital, Neil Cashman, Chief Scientific Officer and Co-Founder, ProMIS Neurosciences, Pallavi Sachdev, Executive Director, Translational Medicine, Eisai, Paul Edison, Professor, Imperial College London, Peter DiBiaso, Patient, The Michael J. Fox Foundation for Parkinson's Research, Ralf Schmid, Associate Director, Pre-Clinical Research, Novartis AG, Rebecca Edelmayer, Vice President, Scientific Engagement, Alzheimer's Association, Sandi See Tai, Chief Devleopment Officer, Lexeo Therapeutics, Sathya Ganesan, US Regulatory Science Lead, UCB S.A., Sean Pintchovski, Vice President, Biology, AcureX Therapeutics, Shane Hegarty, Chief Scientific Officer and Co-Founder, Axonis, Shannon Leslie, Senior Scientist, Johnson and Johnson Services, Inc, Spring Behrouz, Co-founder and CEO, Vincere Biosciences, Steven Arnold, Managing Director, Interdisciplinary Brain Center, Massachusetts General Hopsital, Tammy Dellovade, Senior Research Fellow, Discovery Neuroscience, Abbvie, Tony Bannon, Senior Director - Scientific, Precision Medicine and Neuroscience, Abbvie, Tricia Thornton-Wells, Senior Director and Compound Development Team Leader, Johnson and Johnson Services, Inc, Urs Langen, Lab Head, Roche, William Shrader, Cofounder and Chief Scientific Officer, AcureX Therapeutics, Xavier Langlois, Research Fellow and Head of Tau Pathobiology, Abbvie